Michelle Hanna of Ribomed on Developing Non-PCR Sensor Tech in Phoenix | GenomeWeb

Michelle Hanna is the founder and CEO of Ribomed Biotechnologies, a six-year-old Phoenix-based molecular biology tools startup with approximately $5 million in grants to develop technology for a handheld bioterrorism agents detection device, and the developer of a new laboratory workspace located across the street from the Translational Genomics Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.